# Ajian (Beijing) Gene Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ajian-beijing-gene-technology-co

- Industry: Healthcare
- Headquarters: Beijing, China
- Total disclosed funding: $31M
- Latest round: Angel (Dec 8, 2021)
- Investors on record: 6

## About

Established in 2017 and based in Beijing, China, Ajian (Beijing) Gene Technology Co., Ltd. is a medical health company that focuses on preimplantation genetic diagnosis and precise diagnosis and treatment of infection. At present, the company has established medical testing laboratories, R&D centers and production bases in Fuzhou, Beijing, Shanghai, Zhengzhou, Wuhan, Guangzhou, Chongqing and other places, with a total area of nearly 30,000 square meters.

The company provides preimplantation genetic diagnosis service, preimplantation chromosome screening service and infection precision diagnosis and treatment service for customers. The company has a self developed gene sequencing PathoSeq™ platform has the function of pathogenic microorganism inspection.

The company plans to use the funding for the research, development and upgrading of new technologies and further increase in market size.

## Funding rounds

- Angel, Dec 8, 2021, $31M — Shenzhen HTI, Jinbang Capital, Huahsi PE Fund, Chongqing Boyi Equity Investment Fund Management, Haixia Financial Holdings Group, Haiding Capital

## Investors

- Shenzhen HTI (https://capitalatlas.ai/funds/shenzhen-hti) — Angel
- Jinbang Capital — Angel
- Huahsi PE Fund (https://capitalatlas.ai/funds/huahsi-pe-fund) — Angel
- Chongqing Boyi Equity Investment Fund Management — Angel
- Haixia Financial Holdings Group — Angel
- Haiding Capital — Angel